KeyBanc Remains a Buy on Steris (STE)
KeyBanc analyst Brett Fishbin reiterated a Buy rating on Steris today and set a price target of $269.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
According to TipRanks, Fishbin is an analyst with an average return of -10.0% and a 30.43% success rate. Fishbin covers the Healthcare sector, focusing on stocks such as ICU Medical, Solventum Corporation, and Resmed.
In addition to KeyBanc, Steris also received a Buy from Piper Sandler’s Jason Bednar in a report issued yesterday. However, on the same day, Needham maintained a Hold rating on Steris (NYSE: STE).
Based on Steris’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $1.5 billion and a net profit of $192.8 million. In comparison, last year the company earned a revenue of $1.37 billion and had a net profit of $173.53 million
Based on the recent corporate insider activity of 55 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of STE in relation to earlier this year. Most recently, in March 2026, Cynthia Feldmann, a Director at STE sold 3,098.00 shares for a total of $734,876.58.
